^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cutaneous T-cell Lymphoma |
| Drug: | Lymphir (denileukin diftitox-cxdl) (IL-2 stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
announced today that the U.S. Food and Drug Administration (FDA) has approved LYMPHIR™ (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Published date:
08/08/2024
Excerpt:
...announced today that the U.S. Food and Drug Administration (FDA) has approved LYMPHIR™ (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. LYMPHIR is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs.
